Ambit taps Alan Lewis as CEO

Ambit Biosciences has completed a thorough executive search and appointed Alan Lewis as chairman and CEO of the company. Release

Ablynx Chief Scientific Officer Debbie Law has resigned from her position at Ablynx. Release

iBio has named Terence (Terry) Ryan as senior VP, business development. Release

Roche has announced that Karen Lackey has been named VP and head of medicinal chemistry, effective immediately. Release

Gentris has appointed Karen Weck as a consulting medical director. Dr. Weck replaces the previous medical director to continue Gentris' CLIA program and help expand opportunities to develop new biomarkers. Release

NexMed has announced that Mohamed Hachicha has been appointed to the position of VP, R&D for NexMed USA, effective immediately. Release

Celsion has announced the appointment of Sid Taubenfeld as director of communications and strategic initiatives, effective immediately. Release

Patrick Zenner has been elected to Par Pharmaceutical's board of directors. Zenner was also appointed to the compensation and management development committee and the corporate development review committee. Release

Dynavax Technologies has appointed Daniel Kisner to its board of directors. The addition of Kisner to the Dynavax board brings its membership to ten. Release

Alexza Pharmaceuticals has named Joseph Turner to its board. Release

BioVex has named Kapil Dhingra to its board of directors as a non-executive. Release

Nile Therapeutics has appointed Richard Brewer as executive chairman.  Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.